China News Service, Tianjin, May 8 (Reporter Zhang Daozheng) The reporter learned from the Tianjin Development Zone Management Committee on the 8th that TEDA's stem cell drug research and development has achieved a major breakthrough, and Tianjin's first stem cell drug has entered clinical trials.

  Recently, the Drug Evaluation Center of the State Administration of Drug Administration announced that the clinical trial application (IND) for new drugs for mesenchymal stem cells (umbilical cord) for class I new drugs declared by Tianjin Angsai Cell Genetic Engineering Co., Ltd. has been approved This is also the first stem cell drug in Tianjin to enter clinical trials.

  Clinical trials are an important stage before the launch of Class I new drugs. This approval means that Class I stem cell new drugs independently developed by Tianjin Angsai Cell Genetic Engineering Co., Ltd. have taken an important step from the trial stage to the clinical application stage.

  "The mesenchymal stem cells (umbilical cord) for injection currently approved for clinical trials are mainly used to treat graft-versus-host disease (GvHD), which mainly occurs in patients who have undergone hematopoietic stem cell transplantation." Tianjin Angsai Cell The relevant person in charge of Genetic Engineering Co., Ltd. introduced that these patients have more serious rejection reactions and poorer prognosis. Injectable mesenchymal stem cells (umbilical cord) will hopefully improve the treatment effect and prognosis of patients.

  Tianjin Angsai Cell Genetic Engineering Co., Ltd. has independently developed new mesenchymal stem cell (umbilical cord) drugs for injection since 2004. In 2006, it declared China ’s first umbilical cord mesenchymal stem cell drug. With the deepening of domestic understanding of cell drugs Relevant policies were introduced. After years of unremitting efforts by the R & D team, Angsai ’s stem cell drugs were approved for clinical use this year. The company will continue to increase investment in scientific research to promote the market of this new stem cell drug as soon as possible and apply it to the clinic to enable relevant patients to obtain beneficial. At the same time, the company will continue to increase the research and development of related products in the follow-up to develop a variety of models including cirrhosis, liver failure, lung injury, chronic obstructive pulmonary disease (COPD) and cardio-cerebrovascular ischemic diseases New drug for stem cells.

  After years of development, Tianjin Development Zone has built an internationally competitive biopharmaceutical industrial base. There are a number of new R & D institutions such as the International Biomedicine Joint Research Institute, Tianjin Pharmaceutical Clinical Research and Technology Innovation Center, and 400 biopharmaceutical enterprises. Yujia.

  The relevant person in charge of the Tianjin Development Zone Management Committee said that the next step will focus on scientific and technological innovation in the biopharmaceutical field, reserve a group of key enterprises, increase policy support, guide enterprises to increase scientific and technological input and output of scientific and technological achievements, cultivate high-quality scientific and technological achievements, help Push the Binhai New Area to create a "cell valley" with Beijing-Tianjin-Hebei characteristics. (Finish)